Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
An, Open-label, Multicenter, Randomized, Active Control Study, Comparing P1101 Monotherapy to Entecavir Monotherapy in Patients With HBeAg-negative Chronic Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
Sponsor: National Taiwan University Hospital
A NA clinical study on Chronic Hepatitis B Virus Infection, this trial is ongoing. The trial is conducted by National Taiwan University Hospital and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Feb 2025 — Sep 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jan 2023 — Jul 2024 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Sep 2022 — Jan 2023 [monthly]
Recruiting NA
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Taiwan University Hospital
- PharmaEssentia
For direct contact, visit the study record on ClinicalTrials.gov .